A Direct Comparison of Peptide Drug Delivery Systems Based on the Use of Hybrid Calcium Phosphate/Chitosan Nanoparticles versus Unmixed Calcium Phosphate or Chitosan Nanoparticles In Vitro and In Vivo

Int J Mol Sci. 2023 Oct 24;24(21):15532. doi: 10.3390/ijms242115532.

Abstract

Nanocarriers provide a number of undeniable advantages that could improve the bioavailability of active agents for human, animal, and plant cells. In this study, we compared hybrid nanoparticles (HNPs) consisting of a calcium phosphate core coated with chitosan with unmixed calcium phosphate (CaP) and chitosan nanoparticles (CSNPs) as carriers of a model substrate, enalaprilat. This tripeptide analog is an inhibitor of angiotensin-converting enzyme and was chosen by its ability to lower intraocular pressure (IOP). In particular, we evaluated the physicochemical characteristics of the particles using dynamic light scattering (DLS) and scanning electron microscopy (SEM) and analyzed their ability to incorporate and release enalaprilat. HNPs exhibited the highest drug loading capacity and both HNPs and CSNPs demonstrated slow drug release. The comparison of the physiological effects of enalaprilat-loaded CaP particles, HNPs, and CSNPs in terms of their impact on IOP in rabbits revealed a clear advantage of hybrid nanoparticles over both inorganic and chitosan nanoparticles. These results could have important mechanistic implications for developing nano-based delivery systems for other medical, veterinary, and agricultural applications.

Keywords: angiotensin-converting enzyme inhibitor; calcium phosphate particles; cationic carriers; chitosan; enalaprilat; intraocular pressure.

MeSH terms

  • Animals
  • Calcium Phosphates
  • Chitosan*
  • Drug Carriers
  • Drug Delivery Systems
  • Drug Liberation
  • Enalaprilat
  • Humans
  • Nanoparticles*
  • Particle Size
  • Peptides
  • Rabbits

Substances

  • Drug Carriers
  • Chitosan
  • Enalaprilat
  • Peptides
  • Calcium Phosphates